Access to diagnostic tests and the subsequent reimbursement is an issue affecting all stakeholders in the fast evolving personalized medicine space. It’s an intricate web woven by drug companies, payers, insurance giants, laboratories and national health organizations. And once you think you have [...]
Financial analysts have good reason to anticipate the continued growth of personalized medicine. Not only is it affecting patients and physicians but it holds plenty of promise for the pharma industry. General Strategic Development Benefits Personalized medicine encourages more vertical [...]